Research programme: cyclin dependent kinase inhibitors - Beta Pharma

Drug Profile

Research programme: cyclin dependent kinase inhibitors - Beta Pharma

Alternative Names: BPI 1178

Latest Information Update: 01 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Beta Pharma
  • Class Antineoplastics
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors; Cyclin-dependent kinase-activating kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Breast cancer
  • Research Small cell lung cancer

Most Recent Events

  • 01 Dec 2016 Research programme: cyclin dependent kinase inhibitors - Beta Pharma is available for licensing as of 01 Dec 2016. http://betapharma.com/partnerships-oncology-clinical-research/partnerships-pharma-oncology/
  • 09 Nov 2016 Early research in Small cell lung cancer in USA (unspecified route)
  • 09 Nov 2016 Beta Pharma announces intention to submit a Clinical Trial Application for BPI 1178 to China FDA and US FDA in second quarter of 2017 (Beta Pharma website, November 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top